Cargando…
Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study
OBJECTIVE: To determine the coverage for the oral cholera vaccine (OCV) campaign conducted during the 2017/2018 cholera outbreak in Lusaka, Zambia. STUDY DESIGN: A descriptive cross-sectional study employing survey method conducted among 1691 respondents from 369 households following the second roun...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565249/ https://www.ncbi.nlm.nih.gov/pubmed/37798024 http://dx.doi.org/10.1136/bmjopen-2022-070796 |
_version_ | 1785118658190639104 |
---|---|
author | Mukonka, Victor M Sialubanje, Cephas Matapo, Belem Blamwell Chewe, Orbrie Ngomah, Albertina Moraes Ngosa, Willaim Hamoonga, Raymond Sinyange, Nyambe Mzyece, Hannah Mazyanga, Lucy Bakyaita, Nathan Kapata, Nathan |
author_facet | Mukonka, Victor M Sialubanje, Cephas Matapo, Belem Blamwell Chewe, Orbrie Ngomah, Albertina Moraes Ngosa, Willaim Hamoonga, Raymond Sinyange, Nyambe Mzyece, Hannah Mazyanga, Lucy Bakyaita, Nathan Kapata, Nathan |
author_sort | Mukonka, Victor M |
collection | PubMed |
description | OBJECTIVE: To determine the coverage for the oral cholera vaccine (OCV) campaign conducted during the 2017/2018 cholera outbreak in Lusaka, Zambia. STUDY DESIGN: A descriptive cross-sectional study employing survey method conducted among 1691 respondents from 369 households following the second round of the 2018 OCV campaign. STUDY SETTING: Four primary healthcare facilities and their catchment areas in Lusaka city (Kanyama, Chawama, Chipata and Matero subdistricts). PARTICIPANTS: A total of 1691 respondents 12 months and older sampled from 369 households where the campaign was conducted. A satellite map-based sampling technique was used to randomly select households. DATA MANAGEMENT AND ANALYSIS: A pretested electronic questionnaire uploaded on an electronic tablet (ODK V.1.12.2) was used for data collection. Descriptive statistics were computed to summarise respondents’ characteristics and OCV coverage per dose. Bivariate analysis (χ(2) test) was conducted to stratify OCV coverage according to age and sex for each round (p<0.05). RESULTS: The overall coverage for the first, second and two doses were 81.3% (95% CI 79.24% to 83.36%), 72.1% (95% CI 69.58% to 74.62%) and 66% (95% CI 63.22% to 68.78%), respectively. The drop-out rate was 18.8% (95% CI 14.51% to 23.09%). Of the 81.3% who received the first dose, 58.8% were female. Among those who received the second dose, the majority (61.0%) were females aged between 5 and 14 years (42.6%) and 15 and 35 years (27.7%). Only 15.5% of the participants aged between 36 and 65 and 2.5% among those aged above 65 years received the second dose. CONCLUSION: These findings confirm the 2018 OCV campaign coverage and highlight the need for follow-up surveys to validate administrative coverage estimates using population-based methods. Reliance on health facility data alone may mask low coverage and prevent measures to improve programming. Future public health interventions should consider sociodemographic factors in order to achieve optimal vaccine coverage. |
format | Online Article Text |
id | pubmed-10565249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-105652492023-10-12 Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study Mukonka, Victor M Sialubanje, Cephas Matapo, Belem Blamwell Chewe, Orbrie Ngomah, Albertina Moraes Ngosa, Willaim Hamoonga, Raymond Sinyange, Nyambe Mzyece, Hannah Mazyanga, Lucy Bakyaita, Nathan Kapata, Nathan BMJ Open Epidemiology OBJECTIVE: To determine the coverage for the oral cholera vaccine (OCV) campaign conducted during the 2017/2018 cholera outbreak in Lusaka, Zambia. STUDY DESIGN: A descriptive cross-sectional study employing survey method conducted among 1691 respondents from 369 households following the second round of the 2018 OCV campaign. STUDY SETTING: Four primary healthcare facilities and their catchment areas in Lusaka city (Kanyama, Chawama, Chipata and Matero subdistricts). PARTICIPANTS: A total of 1691 respondents 12 months and older sampled from 369 households where the campaign was conducted. A satellite map-based sampling technique was used to randomly select households. DATA MANAGEMENT AND ANALYSIS: A pretested electronic questionnaire uploaded on an electronic tablet (ODK V.1.12.2) was used for data collection. Descriptive statistics were computed to summarise respondents’ characteristics and OCV coverage per dose. Bivariate analysis (χ(2) test) was conducted to stratify OCV coverage according to age and sex for each round (p<0.05). RESULTS: The overall coverage for the first, second and two doses were 81.3% (95% CI 79.24% to 83.36%), 72.1% (95% CI 69.58% to 74.62%) and 66% (95% CI 63.22% to 68.78%), respectively. The drop-out rate was 18.8% (95% CI 14.51% to 23.09%). Of the 81.3% who received the first dose, 58.8% were female. Among those who received the second dose, the majority (61.0%) were females aged between 5 and 14 years (42.6%) and 15 and 35 years (27.7%). Only 15.5% of the participants aged between 36 and 65 and 2.5% among those aged above 65 years received the second dose. CONCLUSION: These findings confirm the 2018 OCV campaign coverage and highlight the need for follow-up surveys to validate administrative coverage estimates using population-based methods. Reliance on health facility data alone may mask low coverage and prevent measures to improve programming. Future public health interventions should consider sociodemographic factors in order to achieve optimal vaccine coverage. BMJ Publishing Group 2023-10-05 /pmc/articles/PMC10565249/ /pubmed/37798024 http://dx.doi.org/10.1136/bmjopen-2022-070796 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Epidemiology Mukonka, Victor M Sialubanje, Cephas Matapo, Belem Blamwell Chewe, Orbrie Ngomah, Albertina Moraes Ngosa, Willaim Hamoonga, Raymond Sinyange, Nyambe Mzyece, Hannah Mazyanga, Lucy Bakyaita, Nathan Kapata, Nathan Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title | Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title_full | Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title_fullStr | Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title_full_unstemmed | Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title_short | Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study |
title_sort | euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in lusaka district, zambia: a cross-sectional descriptive study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565249/ https://www.ncbi.nlm.nih.gov/pubmed/37798024 http://dx.doi.org/10.1136/bmjopen-2022-070796 |
work_keys_str_mv | AT mukonkavictorm euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT sialubanjecephas euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT matapobelemblamwell euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT cheweorbrie euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT ngomahalbertinamoraes euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT ngosawillaim euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT hamoongaraymond euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT sinyangenyambe euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT mzyecehannah euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT mazyangalucy euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT bakyaitanathan euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy AT kapatanathan euvicholplusvaccinecampaigncoverageduringthe20172018choleraoutbreakinlusakadistrictzambiaacrosssectionaldescriptivestudy |